Inflammatory bowel diseases
Cure8 research brief
Why This Matters
Anti‑TL1A drugs represent a new mechanism with phase 2 signals for clinical remission and endoscopic response in both UC and Crohn's disease, plus early biomarker evidence suggesting antifibrotic effects—areas directly relevant to many people with IBD.
Who Should Pay Attention
Patients with IBD (especially those with fibrostenotic disease or prior biologic exposure), clinicians treating IBD, and researchers in IBD drug development.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The article describes TL1A (TNFSF15) as a target involved in intestinal inflammation and fibrosis and reviews human phase 2 data (remission and endoscopic response ranges reported) plus mucosal and serum biomarker analyses that suggest antifibrotic activity.
It notes at least 19 development programs, including extended‑half‑life antibodies, bispecifics, an oral nanobody, and a DR3 antagonist, and highlights pending phase 3 readouts in 2026–2027 that may clarify efficacy in fibrostenotic disease and biologic‑refractory patients.
The review also mentions companion diagnostic work on TNFSF15 risk variants but says incremental clinical utility is currently modest and will be tested in phase 3 programs.
Keep In Mind
This is a narrative review abstract from the journal Inflammatory Bowel Diseases summarizing phase 2 results and pipeline programs; definitive efficacy and safety for phase 3 candidates are pending.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory bowel diseases
AuthorsMohammed Nabil Quraishi, Vipul Jairath, Badr Al-Bawardy
InstitutionDepartment of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 27, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026
This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
Patients and clinicians considering guselkumab for Crohn’s disease or ulcerative colitis may gain real-world evidence on how the drug performs across treatment lines and subgroups over up to 96 weeks. The study will...